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ORIGINAL ARTICLE
Multimerin-2 is a ligand for group 14 family C-type lectins
CLEC14A, CD93 and CD248 spanning the endothelial
pericyte interface
KA Khan1, AJ Naylor2, A Khan1, PJ Noy1, M Mambretti1, P Lodhia1, J Athwal1, A Korzystka1, CD Buckley2, BE Willcox3, F Mohammed3
and R Bicknell1
The C-type lectin domain containing group 14 family members CLEC14A and CD93 are proteins expressed by
endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour
endothelial marker-1) is also a member of this family and is expressed by tumour-associated ﬁbroblasts
and pericytes. Multimerin-2 (MMRN2) is a unique endothelial speciﬁc extracellular matrix protein that has been
implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and
CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent
on a predicted long-loop region in the C-type lectin domain and is abrogated by mutation within the domain.
CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on
a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the
interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2
spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial
cell surface as well as increasing adherence of human umbilical vein endothelial cells to the active peptide.
This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These ﬁndings identify
novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel
formation.
Oncogene advance online publication, 3 July 2017; doi:10.1038/onc.2017.214
INTRODUCTION
Angiogenesis describes the formation of new blood vessels from
existing ones and is an integral part of reproduction, embryonic
development and wound healing. Although mostly dormant in
healthy adults, it is a component of numerous pathologies including
cancer, diabetic retinopathy and atherosclerosis.1 The ability to
control angiogenesis can provide therapeutic value and under-
standing the underlying molecular events is critical in this pursuit.
The endothelial speciﬁc transmembrane glycoprotein CLEC14A
has been identiﬁed as a tumour endothelial marker, due to its
greater expression in tumour vasculature than vessels in healthy
tissue.2–5 The closely related CD93 is also overexpressed in tumour
endothelium and studies conﬁrm a role in tumour
angiogenesis.6–8 CD248 (endosialin or TEM1) is not expressed by
endothelium but is found on pericytes and tumour-associated
ﬁbroblasts of multiple tumour types.9 These three relatively
understudied glycoproteins are part of the group 14 family of
C-type lectin domain (CTLD) containing proteins.
There is limited information about the molecular pathways that
CLEC14A and CD93 regulate, although functional data have
demonstrated roles for both in endothelial migration and tube
formation.2,5,7 CLEC14A was previously shown to bind an
endothelial speciﬁc extracellular matrix (ECM) protein
multimerin-2 (MMRN2), and antibodies disrupting this interaction
retard angiogenesis and tumour growth, conﬁrming its role in
tumour development.3,10 Furthermore, a meta-analysis of micro-
array data from over 1000 patient samples across three cancer
types identiﬁed CLEC14A, CD93 and MMRN2 as core components
of a proposed ‘tumour angiogenesis signature’.6 Likewise,
CLEC14A and MMRN2 are both upregulated with tumour
progression in spontaneous mouse tumours.10
CD248 has also been shown to have roles in angiogenesis,
particularly in vessel regression during vascular patterning.11
CD248 has been described as a marker of pericytes associated
with glioma vasculature,12 and is elevated in the stroma of many
other tumours including colorectal, melanoma and
glioblastoma.13–15 For these reasons, CD248 is actively being
pursued as a cancer target with clinical trials underway.16
Here we investigate the interactions of the CTLD group 14
family with the CLEC14A ligand MMRN2 and show CLEC14A, CD93
and CD248 all engage MMRN2, whereas thrombomodulin of the
family does not. Our ﬁndings propose previously unknown
protein–protein interactions that occur in endothelium and the
surrounding stroma, providing new targets in anti-angiogenic
treatment.
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RESULTS
CTLD group 14 family members CLEC14A and CD93 directly bind
MMRN2
We previously identiﬁed MMRN2 as a CLEC14A-binding partner,3
to examine whether other CTLD group 14 members also bind
MMRN2, we used far western blotting using a MMRN2 protein
probe to test for direct protein–protein interactions. The CTLD
group 14 members CLEC14A, CD93, thrombomodulin and CD248
were constructed with C-terminal green ﬂuorescent protein (GFP)
tags (Figure 1a), transfected into HEK293T cells and lysates were
separated by SDS–PAGE under non-reducing conditions main-
taining disulphide bonds. Transferred polyvinylidene ﬂuoride
membranes were probed using HEK293T lysates overexpressing
full-length (FL) MMRN2 (MMRN2FL) with a polyhistidine (His) tag.
MMRN2FL bound to CLEC14A and CD93 detected by His tag
antibodies (Figure 1b). Anti-GFP showed expression of each
protein, however, the CD248-GFP band migrated at a lower
molecular weight (~120 kDa) than previously reported (~175 kDa),
or than expected with a GFP tag (~205 kDa),17 suggesting defects
in glycosylation. Indeed, C-terminal tagging of CD248 has been
shown to prevent cell surface expression.18 Therefore, CD248-GFP
is most likely misfolded and we were unable to determine from
this experiment whether CD248 binds MMRN2, this was addressed
in further studies below.
To validate the CD93–MMRN2 interaction in endothelial cells,
human umbilical vein endothelial cell (HUVEC) lysate was
immunoprecipitated with mouse polyclonal MMRN2 antibodies
or previously validated CD93 monoclonal antibody R139.19,20
MMRN2 was enriched in CD93 immunoprecipitations
(Figure 1c) and CD93 enriched in MMRN2 immunoprecipitations
(Figure 1d).
CLEC14A and CD93 bind a non-glycosylated coiled-coil region of
MMRN2
MMRN2 is comprised of three structural domains, an N-terminal
EMI domain, a central coiled-coil domain and a C-terminal C1q
domain.21 To characterize the CLEC14A-binding region, His tagged
MMRN2 constructs were generated, each lacking major domains
(Figure 2a). These included MMRN2FL, EMI and coiled-coil
(MMRN2EMI-CC), coiled-coil and C1q (MMRN2CC-C1q), coiled-coil
alone (MMRN2CC) and the coiled-coil halved (MMRN2133–486 and
MMRN2487–820). The constructs were transfected into HEK293T and
lysates probed with recombinant CLEC14A extracellular domain
with an Fc tag (CLEC14A-ECD-Fc),4 binding occurred on all MMRN2
proteins except MMRN2133–486 and MMRN2FL (Figure 2b). This is
surprising as non-reduced MMRN2FL does bind CLEC14A
(Supplementary Figure S1). Despite this, the CLEC14A-binding
region was clearly within MMRN2487–820.
To further characterize the CLEC14A-binding domain,
MMRN2487–820 was divided in half revealing binding to
MMRN2487–674 (Figure 2c). When further subdivided, binding
occurred within MMRN2530–624 but not MMRN2487–603 or
MMRN2604–674 constructs (Figure 2c). There exists a highly
conserved region within this portion of MMRN2 (residues
588–620), suggesting a potentially evolutionary conserved
CLEC14A-binding motif (Supplementary Figure S2). The non-
binding fragment MMRN2487–603 terminates within this highly
conserved region adding credence to this theory.
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Figure 1. CD93 directly binds to MMRN2. (a) Diagrams of GFP-tagged CTLD group 14 family members showing domain architecture and
relative size with number of amino acids (aa) without the GFP tag. C-type lectin domain (CTLD), sushi, epidermal growth factor (EGF) domain,
transmembrane (TM), cytoplasmic tail (cyto) and green ﬂuorescent protein (GFP) tag are displayed. (b) HEK293T were transfected with GFP-
tagged group 14 family members, lysates were separated by SDS–PAGE under non-reducing conditions and far western blotted with MMRN2
full-length (MMRN2FL), showing MMRN2FL binds CLEC14A and CD93 but not thrombomodulin or CD248, probing with anti-GFP conﬁrmed
expression of all proteins. (c) Immunoprecipitations of CD93 using monoclonal R139 antibody co-immunoprecipitates MMRN2 from HUVEC
lysates. (d) Immunoprecipitations of MMRN2 using mouse polyclonal antibodies co-immunoprecipitates CD93 from HUVEC lysates. CD93 was
detected using goat polyclonal antibodies in each immunoprecipitation experiment. IgG heavy chains included as loading control.
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Due to low expression levels and the failure of MMRN2530–624 to
be efﬁciently expressed and puriﬁed, this fragment was not
pursued further. Work focussed on the second smallest fragment
MMRN2487–674. As this fragment forms disulphide-linked high
molecular weight complexes, which could interfere in down-
stream assays, the two N-terminal cysteine residues were
removed. The resulting MMRN2495–674 construct maintained its
ability to bind CLEC14A (Supplementary Figure S3).
To explore whether this binding domain existed in mice, the
corresponding regions in mouse MMRN2 (495–678) were
expressed in HEK293T and mouse CLEC14A-ECD-Fc far western
blotting revealed positive binding (Supplementary Figure S4). The
human MMRN2495–674 fragment along with the non-CLEC14A-
binding fragment MMRN2495–603 was expressed in E. coli with a
BirA tag for speciﬁc biotinylation.22 Both biotinylated proteins
bound streptavidin (Figure 2d), and biotinylated MMRN2495–674
bound to cell surface expressed CLEC14A and CD93 but not
thrombomodulin, conﬁrming CLEC14A and CD93 bind to a similar
MMRN2 region (Figure 2e).
MMRN2 binding is dependent on the CLEC14A-CTLD
Our previously described CLEC14A–MMRN2 blocking antibody C4
and the non-blocking antibody C2 provide useful tools in
determining important CLEC14A-binding regions.3 To examine
whether monoclonals C1, C3 or C5 also exhibited blocking effects,
CLEC14A-ECD-Fc pull-down assays blocked with control IgG or
C1–C5 were performed on HEK293T MMRN2FL overexpressed
lysates. Blocking was observed by C1, C4 and C5 antibodies but
not C2 or C3 (Figure 3a). C1, C4 and C5 could also block CLEC14A-
ECD-Fc from binding to the HUVEC surface (Figure 3b). These
antibodies only bind in ﬂow cytometry and not western blots
under reducing conditions, offering ideal tools for probing the
natural conformational folding of CLEC14A.
To establish which CLEC14A domain binds MMRN2, CLEC14A
deletion constructs and far western blotting was used. MMRN2FL
failed to bind CLEC14A lacking the CTLD or sushi domain
(Figure 3c). This could be due to MMRN2 binding being
dependent on both domains, or CLEC14A does not fold
correctly when lacking one of these domains. To explore the
latter, chimeric CLEC14A constructs were generated using the
CTLD of the non-MMRN2 binding thrombomodulin (denoted
CLEC14ATHBD(CTLD)) and the sushi of thrombomodulin
(CLEC14ATHBD(sushi)) inserted into full-length CLEC14A-GFP.
Flow cytometry showed lack of binding of all CLEC14A
antibodies to CLEC14ATHBD(CTLD) except moderate C2 binding.
CLEC14ATHBD(sushi) was able to bind all CLEC14A antibodies except
C2 (Figure 3d). This conﬁrmed that the chimeras were correctly
folded and present on the cell surface and showed that binding
epitopes for all anti-CLEC14A antibodies were within the CTLD
except for C2. Similarly, MMRN2495–674 could bind CLEC14ATHBD
(sushi) but not CLEC14ATHBD(CTLD), conﬁrming that the CLEC14A-
CTLD is required for MMRN2 binding (Figure 3d).
CD248 binds to a separate region of MMRN2 from CLEC14A and
CD93
To determine whether the CD248-CTLD binds MMRN2 in a
correctly folded and cell surface expressed form, the domain
was replaced in CLEC14A to create chimera CLEC14ACD248(CTLD).
Figure 2. CLEC14A binds MMRN2 between residues 530 and 624. (a) Diagrams of MMRN2 truncation mutants, showing the elastin microﬁbril
interface (EMI) domain, coiled-coil (CC) domain and complement related C1q domain. The minimal CLEC14A-binding fragment is highlighted
in black. (b and c) HEK293T were transfected with truncation mutants, lysates were separated by SDS–PAGE under reducing conditions and far
western blotted with CLEC14A-ECD-Fc and western blotted with His tag antibodies. (b) The smallest binding fragment was identiﬁed as
MMRN2487–820, MMRN2FL fails to bind CLEC14A-ECD-Fc. (c) Further truncation mutants were far western blotted revealing the smallest MMRN2
fragment binding CLEC14A is MMRN2530–624. (d) Puriﬁed MMRN2495–674 and MMRN2495–603 bind to streptavidin under reducing conditions
after biotinylation. (e) Flow cytometry histograms of HEK293T transfected with GFP-tagged CTLD group 14 family members and stained with
biotinylated MMRN2495–674 (grey line), conﬁrming binding to CLEC14A and CD93 but not thrombomodulin. Streptavidin-PE alone was used as
a control for background binding (grey shaded).
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This was expressed in HEK293T and lysates far western blotted
under non-reducing conditions revealed binding by MMRN2FL
(Figure 4a). To test whether the sushi domain of CD248 was
sufﬁcient to confer correct folding of CLEC14A-CTLD the chimera
CLEC14ACD248(sushi) was generated, this also bound MMRN2FL.
To ensure GFP-tagged wild-type (wt) and chimeric proteins
were expressed at the cell surface, transfected HEK293T were cell
surface biotinylated before anti-GFP immunoprecipitation. Prob-
ing with streptavidin-horse radish peroxidase (HRP) conﬁrmed
CLEC14A, CD93, thrombomodulin and chimeras were expressed
on the cell surface (Figure 4b).
To determine where CD248 binds MMRN2, truncation mutants
were transfected into HEK293T and lysates subjected to far
western blot analysis. Mouse CD248-ECD-Fc that had been
previously shown to bind human endothelial ECM was used as a
probe.11 CD248-ECD-Fc bound to MMRN2133–486, a completely
distinct region than required for CLEC14A or CD93 binding
(Figure 4c). To test whether mCD248-ECD-Fc could bind MMRN2
from HUVEC, pull-down assays were performed on lysates,
revealing enrichment of MMRN2 (Figure 4d).
To determine whether previous mCD248-ECD-Fc ECM staining
experiments were due to binding MMRN2,11 mCD248-ECD-Fc and
polyclonal MMRN2 antibodies were used to stain cultured HUVEC.
MMRN2 staining revealed ﬁbrous meshes in the ECM partially co-
localizing with mCD248-ECD-Fc or CLEC14A-ECD-Fc binding but
not hFc alone (Figure 4e).
To determine whether CLEC14A and CD248 can bind MMRN2
simultaneously, a sandwich ELISA (enzyme-linked immunosorbent
assay) approach was taken. This showed CD248 could capture
MMRN2 (Figure 4f), and CD248 could also capture MMRN2, which
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Figure 3. MMRN2 binds to CLEC14A in the C-type lectin domain. (a) CLEC14A-ECD-Fc pull-downs were pre-incubated with either PBS, mouse
control IgG, or CLEC14A monoclonal antibodies C1–5 and used to pull down MMRN2FL from HEK293T-transfected lysates. C1, C4 and C5
blocked MMRN2 enrichment, whereas C2 and C3 did not. (b) Flow cytometry analysis of CLEC14A-ECD-Fc binding to HUVEC surface.
CLEC14A-ECD-Fc was pre-incubated with the same blocking conditions as in pull-downs. C1, C4 and C5 signiﬁcantly blocked CLEC14A-ECD-Fc
binding to HUVEC surface. (*Po0.05 Mann–Whitney test n= 4) error bars represent standard error mean (s.e.m.). (c) HEK293T transfected with
CLEC14A domain deletions were lysed and far western blotted with MMRN2FL under non-reduced conditions. Upon detection of the
MMRN2FL His tag, MMRN2 binding was observed in all mutants except those lacking the CTLD or sushi domains. Probing with anti-CLEC14A
antibodies was included to show expression of each mutant protein. (d) Flow cytometry analysis of HEK293T transfected with CLEC14A wild-
type (wt) with a GFP tag, chimera 1 CLEC14ATHBD(CTLD) or chimera 2 CLEC14ATHBD(sushi). All of the CLEC14A monoclonal antibodies and
MMRN2495–674 bound to CLEC14A wt. None of the CLEC14A monoclonal antibodies nor the MMRN2495–674 fragment bound to chimera 1
CLEC14ATHBD(CTLD) except modest binding with C2. All antibodies except C2 bound to chimera 2 CLEC14ATHBD(sushi). The MMRN2495–674
fragment could also bind chimera 2 CLEC14ATHBD(sushi).
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subsequently bound CLEC14A, conﬁrming these proteins do not
compete for binding with MMRN2 (Figure 4g). This suggests
CLEC14A or CD93 expressed by endothelial cells can bind MMRN2
at the same time as CD248 expressed by ﬁbroblasts or pericytes
(Figure 4h). Descriptions of each MMRN2 truncation and which
CTLD group 14 members bind are summarized in Supplementary
Table 1.
To determine whether the CLEC14A–MMRN2–CD248 interaction
could be observed in human cancer, pancreatic tumours were
stained with antibodies against each protein, revealing separate
CLEC14A and MMRN2 expression from CD248. In some areas, co-
localization of all three proteins can be seen at the interface
between CLEC14A-positive endothelial cells and CD248-positive
cells, likely to be pericytes. (Figure 5).
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with mCD248-ECD-Fc, revealing binding to minimal fragment MMRN2133–486. His tag western blot conﬁrmed expression of each MMRN2
protein fragment. (d) mCD248-ECD-Fc pull-downs from HUVEC lysates resulted in enrichment of MMRN2 compared with hFc control.
(e) Immunoﬂuorescence analysis of HUVEC stained with MMRN2 mouse polyclonal antibodies, hFc, mCD248-ECD-Fc or CLEC14A-ECD-Fc.
MMRN2 antibody staining partially co-localizes with CD248-ECD-Fc and CLEC14A-ECD-Fc binding; scale bar, 40 μm. (f) ELISAs of mCD248-ECD-
Fc bound to plate capturing MMRN2 FL His, (**Po0.01 Mann–Whitney test, n= 5) error bars represent s.e.m. (g) ELISAs of mCD248-ECD-Fc
capturing MMRN2 FL His and then binding by CLEC14A-ECD-Fc detected by anti-CLEC14A antibody C2. (**Po0.01 Mann–Whitney test, n= 5)
error bars, s.e.m. (h) Diagram of CLEC14A or CD93 expressed by endothelial cells binding to MMRN2 in the ECM, which in turn is bound by
CD248 expressed by ﬁbroblasts or vasculature associated pericytes. CD248, CLEC14A and CD93 binding is due to the CTLD, CD248 binds
MMRN2 in the region 133–486, whereas CLEC14A binds in the region 530–624.
MMRN2 binds three group 14 family C-type lectins
KA Khan et al
5
Oncogene (2017) 1 – 12
MMRN2 binding is dependent on a CTLD long-loop region in
CLEC14A and CD93
To visualize the three-dimensional orientation of the CLEC14A-CTLD
and potential MMRN2 recognition surfaces, a predicted molecular
model of the CLEC14A-CTLD was generated using the iTASSER
server.23 This model exhibited characteristics of the CTLD fold,
including a ‘loop in a loop’ structure with a hydrophobic core24
(Figure 6a), and revealed the close proximity of six cysteine residues
that are canonical in CTLDs suggesting disulphide bond formation
(Figure 6b). There are also two non-canonical cysteines within the
long-loop region that are distal from each other (C103 and C138).
The CLEC14A-CTLD model displays a similar overall structure to the
crystal structure of human tetranectin25 (Figure 6c).
A previous study demonstrated that CTLD-speciﬁc CLEC14A
antibodies had similar anti-angiogenic effects as observed with
our C4 antibody, we hypothesized that these may block the
CLEC14A–MMRN2 interaction.26 These CTLD-speciﬁc antibodies
have been described to bind epitopes spanning amino acids 1–42
or 122–142 of CLEC14A.27 These regions were mapped onto the
predicted CLEC14A-CTLD model, revealing 1–42 is proximal to the
sushi domain boundary and 122–142 is on the long loop. There
also existed another region (97–108), which was semi-conserved
in CD93 and part of the predicted long loop (Figure 6d and
Supplementary Figure S5). To test whether epitopes for our
antibodies or regions important for MMRN2 binding were
within these regions, CLEC14A chimeras were generated by
swapping with corresponding regions of thrombomodulin.
CLEC14ATHBD(1–42) and CLEC14ATHBD(122–142) chimeras failed to
bind antibodies C1–C5 suggesting they were incorrectly folded,
and were not used for further experiments (data not shown). In
contrast, the CLEC14ATHBD(97–108) mutant could bind C2 and C3
but not the CLEC14A–MMRN2 blocking antibodies C1, C4 or C5,
MMRN2 CLEC14A
CD248Nuclei
Merge
CD248 CLEC14A MMRN2
Nuclei
i
ii
i
ii
Merge
Figure 5. CLEC14A–MMRN2–CD248 co-localization can be observed in human pancreatic cancer. Human pancreatic cancer sections were
stained with antibodies against CD248 (green), CLEC14A (red) and MMRN2 (blue), Hoescht was used to visualize nuclei (grey). (a) CD248-
positive cells (likely pericytes) are in close proximity to CLEC14A- and MMRN2-positive endothelial cells. This revealed co-localization of
CLEC14A and MMRN2 in association with CD248-positive cells. Dotted lines highlight areas that have been enlarged (i and ii). Scale bars,
50 μm. (b) Partial co-localization of CLEC14A and MMRN2 where they meet CD248-positive cells. Co-localization of all three proteins is
indicated in white. The merged image displays orthogonal views in xz and yz. Scale bars, 10 μm.
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Figure 6. CLEC14A and CD93 bind MMRN2 in long-loop region of the CTLD. (a) CLEC14A-CTLD iTASSER generated molecular model,
displaying long-loop region in red and numbered α-helices and β-sheets. (b) CLEC14A-CTLD model displaying predicted arrangement of
cysteine residues. Cysteines C31, C37, C54, C143, C162 and C171 are canonical CTLD fold cysteines and are in close proximity to form
disulphide bonds. C103 and C138 are non-canonical cysteines present in the long-loop region. (c) Solved crystal structure of tetranectin CTLD
(1TN3), displaying long-loop region in red and numbered α-helices and β-sheets. (d) CLEC14A-CTLD model with predicted antibody epitopes
1–42 (showing 21–42 in the model, blue), 122–142 (orange) and region 97–108 (grey). (e) Flow cytometry analysis of HEK293T transfected with
CLEC14ATHBD(97–108), CLEC14AC103S or CLEC14AC138S. Only C2 and C3 bind to CLEC14ATHBD(97–108), all C1–5 bind CLEC14AC103S and
CLEC14AC138S all CLEC14A mutant proteins fail to bind MMRN2495–674. (f) Flow cytometry analysis of HEK239T transfected with CD93 wt,
CD93C104S or CD93C136S. All proteins bind R139 antibody showing correct conformational folding and presence at the cell surface, although
both CD93C104S and CD93C136S fail to bind MMRN2495–674.
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indicating the binding epitopes for these antibodies are within
this region (Figure 6e). MMRN2495–674 also failed to bind
CLEC14ATHBD(97–108) as expected. The 97–108 region contained
the amino acids 97ERRRSHCTLENE108, to test whether the non-
canonical cysteine (C103) within this sequence forms disulphide
bonds that are important for MMRN2 binding, the mutant
CLEC14AC103S was generated along with the other non-canonical
long-loop cysteine (CLEC14AC138S). These mutants could bind all
CLEC14A monoclonals C1–C5 suggesting they were correctly
folded. However, they failed to bind MMRN2495–674, highlighting
the importance of these residues for CLEC14A–MMRN2 interac-
tions (Figure 6e).
As CD93 also contains two non-canonical cysteines in the
predicted long-loop region, the mutants CD93C104S and CD93C136S
Figure 7. MMRN2495–674 inhibits angiogenesis in vitro. (a) Representative ﬂow cytometry histograms of CLEC14A-ECD-Fc pre-incubated with
MMRN2495–674 or MMRN2495–603 and then used to stain HUVEC surface, hFc used as isotype control. (b) MMRN2495–674 signiﬁcantly blocked cell
surface binding. (*Po0.05 Mann–Whitney test n= 4). (c) Representative images of MMRN2495–603 and MMRN2495–674 coated plates with
adherent HUVEC stained with crystal violet; scale bar, 150 μm. (d) HUVEC adhered signiﬁcantly more to MMRN2495–674 compared with
MMRN2495–603 or bovine serum albumin (BSA; **Po0.01 Mann–Whitney test, n= 6). (e) HUVEC were added to Matrigel and treated with PBS,
hFc, CLEC14A-ECD-Fc (CLEC14A-Fc) MMRN2495–603 or MMRN2495–674. Representative images from 6, 12 and 24 h post Matrigel plating from
one of three independent experiments; scale bar, 100 μm. (f) Quantiﬁcation of number of meshes at 6, 12 and 24 h time points, average values
from eight ﬁelds of view from three independent experiments, (*Po0.05, **Po0.01 unpaired t-test, n= 3, error bars represent s.e.m.).
(g) Representative images of HUVEC-ﬁbroblast co-culture assay from three different umbilical cords. Scale bar, 800 μm. (h) Quantiﬁcation of
number of tubules and total tubule length, from averages of four ﬁelds of view from three independent experiments. (*Po0.05 unpaired
t-test, n= 3, error bars represent s.e.m.).
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were generated. The monoclonal R139 anti-CD93 antibody is
conformation-sensitive and was used to validate correct folding
and cell surface expression of CD93 mutants. Both cysteine
mutants along with CD93 wild-type (wt) could bind R139 but
mutants failed to bind MMRN2495–674 (Figure 6f). This conﬁrmed
the necessity of these cysteines for CD93–MMRN2 interactions as
observed for CLEC14A–MMRN2.
The CLEC14A and CD93 binding fragment of MMRN2 inhibits
angiogenesis in vitro
To test whether blocking CLEC14A and CD93 interacting with
MMRN2 can affect angiogenesis, the MMRN2495–674 fragment and
the non-binding MMRN2495–603 fragment were expressed and
puriﬁed from E. coli (Supplementary Figure S6). The same
experiment as Figure 3b was performed testing blocking function
of MMRN2495–674 or MMRN2495–603 on CLEC14A-ECD-Fc binding to
HUVEC. This resulted in signiﬁcant blocking with MMRN2495–674
(Figures 7a and b).
MMRN2 was previously shown to increase HUVEC adherence.28
To test whether the MMRN2495–674 fragment could also increase
adherence, the plates were coated with MMRN2495–674,
MMRN2495–603 or BSA control, resulting in HUVEC adhering to
MMRN2495–674 but not MMRN2495–603 or BSA (Figures 7c and d).
The MMRN2495–674 and MMRN2495–603 fragments were next
examined in angiogenesis assays. As we have previously shown,
CLEC14A-ECD-Fc has anti-angiogenenic effects,4 this was included
in all assays as a positive control along with human IgG Fc alone to
account for effects of the Fc tag. Recombinant proteins were
added to HUVEC in Matrigel tube formation assays resulting in
signiﬁcant decreases in tubule mesh formation with CLEC14A-
ECD-Fc and MMRN2495–674 compared with Fc and MMRN2495–603
respectively (Figures 7e and f). Recombinant proteins were then
tested in the organotypic human ﬁbroblast-HUVEC co-culture
assay,29 resulting in modest reductions in the number of tubules
and total tubule length when treated with MMRN2495–674, but in
this case not when treated with CLEC14A-ECD-Fc (Figures 7g
and h). Intriguingly, CLEC14A-ECD-Fc treatments in co-cultures
induced formation of knot-like areas with high density of tubules.
The CLEC14A and CD93 binding fragment of MMRN2 reduces
tumour growth
To test whether disrupting CLEC14A and CD93 interactions had an
effect on tumour growth in vivo, the mouse MMRN2495–678
fragment and the mouse CLEC14A-ECD were fused to a mouse
IgG Fc tag. These constructs included the signal peptide of mouse
CLEC14A (mCLEC14A) to allow secretion along with murine Fc as a
control (Figure 8a). Lewis lung carcinoma (LLC) cells were
separately lentivirally transduced with these constructs, achieving
greater than 90% transduction efﬁciency (Supplementary
Figure S7). This Fc-fusion strategy was utilized to increase serum
half-life and allow these proteins to be expressed at local sites of
neo-angiogenesis by cells of mouse origin. Western blots of
conditioned media conﬁrmed secretion (Figure 8b). Transduced
LLC cells were shown to have no differences in proliferation
in vitro (Supplementary Figure S8), and were subcutaneously
injected into the ﬂanks of C57BL/6 mice. Tumour growth was
monitored by daily calliper measurements, revealing growth
delays in mMMRN2495–678mFc LLC tumours compared with mFc
(Figure 8c). End tumour weights revealed a signiﬁcant reduction in
mMMRN2495–678mFc expressing LLC (Figures 8d and e). There was
no signiﬁcant difference in the weights or growth rates of
mCLEC14A-ECD-mFc expressing tumours. Immunoﬂuorescence
analysis of CD31-positive vessels revealed no clear differences
between mFc and mMMRN2495–678mFc (Figures 8f–i), although
Figure 8. Mouse MMRN2495–678 reduces tumour growth. (a) Diagrams of constructs used to transduce Lewis lung carcinoma cells. Mouse
hinge region (H), Constant heavy chain 2 and 3 (CH2 and CH3) were fused to mouse CLEC14A signal peptide (SP) to allow secretion of mouse
Fc (mFc). Mouse Fc was also fused to mouse CLEC14A-ECD (mC14A mFc) and mouse MMRN2495–678 (m495-678 mFc). (b) Western blots
detecting mouse Fc tag in conditioned media of LLC transduced with each fusion gene. All proteins are secreted and form dimers under non-
reduced conditions. (c) Tumour volume was measured from days 6 to 14 post implantation. The same mFc control group are plotted on each
graph to allow comparison with m495-678 mFc or mC14A mFc (*Po0.05 Mann–Whitney test, n= 7). (d) Representative image of tumours
from mFc and m495-678 mFc LLC post excision. Scale bar, 10 mm. (e) End-point tumour weight of mFc, mC14A mFc and m495-678 mFc.
(*Po0.05 Mann–Whitney test, n= 7). Error bars represent s.e.m. (f) Quantiﬁcation of total area of CD31 immunoﬂuorescence staining from
mFc and m495-678 mFc tumour sections. (g) Average area stained positively for CD31. (h) Vessel density as a percentage of CD31 staining per
ﬁeld of view. (f–h) Averages of ﬁve ﬁelds of view from each tumour (n= 3). (i) Representative images of CD31 immunoﬂuorescence staining of
mFc and m495-678. Scale bar, 100 μm.
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due to the defects observed in angiogenesis assays, it is possible
that these vessels while present, are non-functional.
DISCUSSION
The CTLD group 14 family are important emerging molecules in
tumour angiogenesis. Our present study has demonstrated CD93
and CD248 as being able to bind the CLEC14A ECM ligand
MMRN2. These interactions have been dissected and found to
involve a predicted long loop in the CTLD of CLEC14A and CD93,
and regions of MMRN2 within its coiled-coil domain. The CLEC14A
and CD93 binding fragment of MMRN2 had anti-angiogenic
effects presumably by disrupting normal CLEC14A and CD93
function.
MMRN2 binding is the ﬁrst description of an extracellular ligand
for CD93 and explains previous observations, such as the ability of
CD93-CTLD-Fc to stain endothelium in human tonsils and CD93
roles in cell adhesion.30,31 CD93 is also important in endothelial
migration and tube formation, CD93-deﬁcient mice exhibit
angiogenesis defects in tumour models phenocopying observa-
tions made for CLEC14A.2,3,5,7,32 We hypothesize that such effects
are potentially due to no longer being present to bind MMRN2.
The CD248–MMRN2 interaction also offers explanations to
previous ﬁndings. The CD248-ECD has been used as a binding
probe in immunoﬂuorescence studies on mouse tissues and
cultured cells,11 revealing characteristic ECM staining only
occurring on endothelial cells, likely dependent on MMRN2.
CD248–MMRN2 interactions occur on a separate region from
CLEC14A and CD93 binding, suggesting endothelial expressed
CTLD group 14 members can bind to MMRN2 simultaneously with
CD248 expressed by other cell types such as pericytes or
ﬁbroblasts. Indeed, this is the case for CLEC14A–MMRN2–CD248
interactions in pancreatic cancer. This offers a scenario where
MMRN2 acts as an ‘extracellular glue’ between both cell types in
vessel formation and maturation. This adds to the list of ECM
proteins along with collagens I and IV and ﬁbronectin already
described as potential CD248 ligands.33
We have dissected the molecular characteristics of these
interactions, revealing a predicted long-loop region within both
CLEC14A and CD93 CTLDs where two conserved cysteine residues
are essential for MMRN2 interactions. These cysteines are likely to
be important in the local conformation of the long-loop region
and disulphide bond formation may be important. As the
conformation-sensitive CLEC14A antibodies bind to both of these
cysteine mutants, disruptions in the folding of the whole CLEC14A
molecule have been ruled out. Nevertheless, although these
residues are not important for antibody binding, they are vital for
binding to MMRN2.
The relevance of MMRN2 in angiogenesis has been previously
demonstrated, two studies describe it as an angiostatic molecule,
acting by sequestering VEGF-A.28,34 However, our studies and
those by Zanivan et al.10 describe MMRN2 as a pro-angiogenic
molecule binding to cell surface proteins. These conﬂicting roles
could be context dependent, where CLEC14A, CD93 and CD248
interactions are separate from those of VEGF-A. Our observations
of HUVEC adhering to MMRN2495–674 could explain the calcium-
independent adhesion described for MMRN2FL, with CLEC14A,
CD93 or both eliciting this adhesive effect.28
CLEC14A and CD93 may have similar roles in ECM interactions,
although it is unclear whether these interactions have distinct
signalling outcomes or compensatory roles. As CD93 is expressed
by other cell types such as haematopoietic cells and platelets,35
these are also likely to bind MMRN2 and the endothelial ECM.
Future studies will shed light on the roles of CLEC14A, CD93 and
CD248 and the signalling of these understudied molecules.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies: anti-CLEC14A mouse monoclonals C1–C5 generated in our
laboratory,3 anti-CLEC14A sheep polyclonal (R&D Systems, Abingdon, UK,
#AF4968), mouse anti-His clone AD1.1 (R&D Systems, #MAB050), anti-GFP
mouse clone 3E1 (Cancer Research UK), anti-MMRN2 mouse polyclonal
(Abnova/Novus Biologicals, Abingdon, UK, #H00079812-B01P), anti-
MMRN2 rabbit polyclonal (Abcam, Cambridge, UK, #ab171314), anti-
CD93 mouse clone R139 (Thermo Fisher Scientiﬁc, Rugby, UK, #14-0939),
anti-CD93 goat polyclonal (R&D Systems, #AF2379), anti-CD248 mouse
clone B1.35 (hybridoma supernatants), anti-CD31 mouse clone JC70A
(Dako, Cambridge, UK, #M0823), anti-Tubulin mouse clone DM1A (Sigma-
Aldrich, Gillingham, UK, #T9026), anti-ﬁbronectin sheep polyclonal (R&D
Systems, #AF1918), anti-CD31 rat clone MEC13.3 (BD Bioscience, Oxford,
UK, #565629), mouse IgG isotype control (Thermo Fisher Scientiﬁc,
#10400C), human IgG Fc (Bethyl Laboratories, Cambridge, UK, #P80-104)
(sodium azide removed by dialysis in phosphate-buffered saline (PBS)),
anti-human IgG Fc HRP conjugated (Sigma-Aldrich, #A0170), anti-mouse
HRP (Dako, #P0447), anti-sheep HRP (R&D Systems, #HAF016), anti-goat
HRP (Dako, #P0449), streptavidin HRP (GE Healthcare, Amersham, UK,
#RPN1231) anti-mouse alexaﬂuor-555 (Thermo Fisher Scientiﬁc, #A21425),
anti-human IgG alexaﬂuor-555 (Thermo Fisher Scientiﬁc, #A21433), anti-
mouse alexaﬂuor-488 (Thermo Fisher Scientiﬁc, #A11001), anti-rabbit
alexaﬂuor-647 (Thermo Fisher Scientiﬁc, #A31573), anti-sheep alexaﬂuor-
546 (Thermo Fisher Scientiﬁc, #A21098), anti-hFc FITC conjugated
(Sigma-Aldrich, #F9512), streptavidin R-phycoerthrin (PE) conjugate
(Thermo Fisher Scientiﬁc, #S-866), ﬁbronectin (Sigma-Aldrich, #F2006).
CD248-ECD-Fc as used.11
Plasmid construction
All CTLD 14 members, mutants and chimeras inserted between EcoRI in
pEGFPN1, using Gibson assembly according to manufacturer (New England
Biolabs, Hitchin, UK), using PCR products ampliﬁed with the following primers;
CLEC14A-forward 5′-GATCTCGAGCTCAAGCTTCGATGAGGCCGGCGTTCGCC-3′,
CLEC14A-reverse 5′-TACCGTCGACTGCAGTGCATCACTAGAGCCAAG-3′, CD93-
forward 5′-CGAGCTCAAGCTTCGATGGCCACCTCCATGGGC-3′, CD93-reverse
5′-TACCGTCGACTGCAGGCAGTCTGTCCCAGGTGTCG-3′, THBD-forward 5′-CG
AGCTCAAGCTTCGATGCTTGGGGTCCTGGTC-3′, THBD-reverse 5′-TACCGTCGAC
TGCAGGAGTCTCTGCGGCGTCCG-3′, CD248-forward 5′-CGAGCTCAAGCTTCGA
TGCTGCTGCGCCTGTTG-3′, CD248-reverse 5′-TACCGTCGACTGCAGTCACACGC
TGGTTCTGCAG-3′. For chimeras, two PCR products or more were Gibson
assembled using; (CLEC14ATHBD(CTLD); THBD-forward and THBD-CTLD fused to
CLEC14A-sushi-reverse 5′-CTCAAACTGGAACTCGCAGAGGAAGCC-3′, THBD-
CTLD fused to CLEC14A-sushi-forward 5′-GCGAGTTCCAGTTTGAGGTCTTG
TGTC-3′ and CLEC14A-reverse). (CLEC14ATHBD(sushi); CLEC14A-forward and
CLEC14A-CTLD fused to THBD-sushi-reverse 5′-TACCGTCGACTGCAGTGCATC
ACTAGAGCCAAG-3′, CLEC14A-CTLD fused to THBD-sushi-forward 5′-GTG
CAAGTACCACTTCCCAGCCACCTGCAGGC-3′ and THBD-sushi fused to CL
EC14A-EGF-reverse 5′-TCCCGGGGCAAGCGCCCGGCGCCTCCCT-3′, THBD-sushi
fused to CLEC14A-EGF-forward 5′-GCCGGGCGCTTGCCCCGGGAGGTACCTC-3′
and CLEC14A-reverse). (CLEC14AC103S; CLEC14A-forward and CLEC14AC103S-
reverse 5′-CTCGTTCTCCAGGGTTGAGTGGGAACGCCTGCGCTC-3′, CLEC14
AC103S-forward 5′-GAGCGCAGGCGTTCCCACTCAACCCTGGAGAACGAG-3′ and
CLEC14A-reverse). (CLEC14AC138S; CLEC14A-forward and CLEC14AC138S-
reverse 5′-CGCGCATCTCCGCGCGGTGGAGGAGCGTTGGGGCTCCTC-3′, CLEC1
4AC138S-forward 5′-GAGGAGCCCCAACGCTCCTCCACCGCGCGGAGATGCGCG-3′
and CLEC14A-reverse). (CLEC14ACD248(sushi); CLEC14A-forward and CLEC14A-C
TLD fused to CD248-sushi-reverse 5′-CCTCGAAGCCGTACTTGCACAGGTA
GCCGTTGGC-3′, CLEC14A-CTLD fused to CD248-sushi-forward 5′-GTGCAAG
TACGGCTTCGAGGGCGCCTGC-3′ and CD248-sushi fused to CLEC14A-EGF-
reverse 5′-TCCCGGGGCAGCCAGTCCCCAGGCACAGG-3′, CD248-sushi fused to
CLEC14A-EGF-forward 5′-GGGGACTGGCTGCCCCGGGAGGTACCTC-3′ and
CLEC14A-reverse). (CLEC14ACD248(CTLD); CD248-forward and CD248-CTLD
fused to CLEC14A-sushi-reverse 5′-CTCAAACTGAAACTGGCACAGGTAGCCG-3′,
CD248-CTLD fused to CLEC14A-sushi-forward 5′-GCCAGTTTCAGTTTGA
GGTCTTGTGTC-3′ and CLEC14A-reverse).
MMRN2 fragments were ampliﬁed using; (MMRN2EMI-CC; MMRN2FL-forward
5′-CCGGACCGGTCAGGCTTCCAGTACTAGCC-3′ and MMRN2820-reverse 5′-CT
ACTAGGTACCCCAGAGCGCCGCGCCC-3′). (MMRN2CC-C1q; MMRN2133-forward
5′-CCGGACCGGTGATTCCATGGCAATCCCTGA-3′ and MMRN2FL-reverse 5′-CG
GGGTACCGGTCTTAAACATCAGGAAGC-3′). (MMRN2CC; MMRN2133-
forward and MMRN2820-reverse). (MMRN2133–486; MMRN2133-forward
and MMRN2486-reverse 5′-CTACTAGGTACCCTTGATGAGGTCGGCATGG-3′).
(MMRN2487–820; MMRN2487-forward 5′-CCGGACCGGTTACGTGAAGGACTGC
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AATTG-3′ and MMRN2820-reverse), (MMRN2487–674; MMRN2487-forward and
MMRN2674-reverse 5′-CTACTAGGTACCCGGCCGCGGGGGCTCCG-3′) (MMR
N2675–820; MMRN2675-forward 5′-CCGGACCGGTGCAGAGCACCTGGAGCC-3′
and MMRN2820-reverse) (MMRN2487–603; MMRN2487-forward and MMRN2603-
reverse 5′-CTACTAGGTACCCGCGTCCTCCAGCAGGG-3′) (MMRN2604–674;
MMRN2604-forward 5′-CCGGACCGGTCTGCGGCACGAGGCGGTG-3′ and MMR
N2674-reverse) (MMRN2530–624; MMRN2530-forward 5′-CCGGACCGGTGGC
TCCTCCCTGCAGGCC-3′ and MMRN2624-reverse 5′-CTACTAGGTACCCTCA
GACATCTCCTCCAGC-3′) (MMRN2495–674; MMRN2495-forward 5′-TAGTAGA
CCGGTCAGAAGCTCTATTTAGACCTG-3′ and MMRN2674-reverse). (Mouse MM
RN2495–678; mMMRN2495-forward 5′-CCGGACCGGTCAAAGGGTCAACTCTGACG
TG-3′ and mMMRN2678-reverse 5′-CTACTAGGTACCCAACTGTGGGTGCTGC
TCC-3′). AgeI and KpnI digested PCR products were ligated into pHL-
Avitag3 containing; N-terminal signal peptide (SP), C-terminal BirA and His
tag (avitag).36
Codon optimized MMRN2495–674 and MMRN2495–603 DNA was synthe-
sized (IDT Technologies, Leuven, Belgium) with ends complementary to
pET23a vector and Gibson assembled in between NdeI and NotI. The
BirA sequence 5′-GGTGGTGGTCTGAACGATATTTTTGAAGCTCAGAAAATCGA
ATGG-3′ was used.
Lentiviral vectors were Gibson assembled between PmeI sites using
primers: mCLEC14A-ECD; forward 5′-ACTAGCCTCGAGGTTTAAACATGAG
GCCAGCGCTTGCC-3′ and reverse 5′-CACTCGATGAGGATCCGGAAGAGG
TGTCGAAAGTCAGAGAAAC-3′, mouse Fc for fusion to mCLEC14A-ECD-
forward 5′-CCTCTTCCGGATCCTCATCGAGTGTGCCCAGGGATTGTGGT-3′ and
reverse 5′-CTGCAGCCCGTAGTTTTCATTTACCAGGAGAGTGGG-3′. mFc alone
fused to CLEC14A SP; mCLEC14A SP-forward 5′-AGACTAGCCTCGA
GGTTTAAACATGAGGCCAGCGCTTGC-3′ and mCLEC14A SP-reverse 5′-
TGAGGATCCCTCCCCATTCCCTGGCCG-3′, mFc fused to SP; forward
5′-AATGGGGAGGGATCCTCATCGAGTGTG-3′ and reverse 5′-TCCTGCAGC
CCGTAGTTTTCATTTACCAGGAGAGTGG-3′. mMMRN2495–678 inserted
between engineered BamHI site separating the SP and mFc; forward 5′-C
AGGGAATGGGGAGGGATCCCAAAGGGTCAACTCTGACG-3′ and reverse 5′-G
GCACACTCGATGAGGATCCCAACTGTGGGTGCTGCTC-3′. Human and mouse
MMRN2, human and mouse CLEC14A, CD248 and thrombomodulin
ampliﬁed from IMAGE clones, mFc ampliﬁed from cDNA of C3 hybridomas.
CD93 ampliﬁed from pCDNA3-CD93, a gift from Suzanne Bohlson.
CLEC14A domain deletions are as previous.4
Protein expression and puriﬁcation
CLEC14A-ECD-Fc was expressed and puriﬁed as described.3 MMRN2495–674
and MMRN2495–603 with His tag or avitag were expressed in E. coli strain
BL21-DE3 pLysS (Promega, Southampton, UK) by induction with 0.5 mM
IPTG at OD600 0.6 and grown at 18 °C overnight. The cell pellets were
homogenized by high pressure lysis (17 000 p.s.i.) in Emulsiﬂex-C3 (4 °C;
Avestin, Winchester, UK) in buffer; 50 mM Na2PO4 pH 7.4 400 mM NaCl, 10%
(v/v) glycerol, 50 mM imidazole, 0.5 mM TCEP and complete EDTA-free
protease inhibitors (Roche, Burgess Hill, UK), then loaded onto Nickel-NTA
columns. Fractions eluted using 500 mM imidazole were puriﬁed by size
exclusion chromatography on S200 columns on an AKTA FPLC machine
(GE Healthcare) in buffer; 20 mM Tris pH8.0, 50 mM NaCl. Proteins were
buffer exchanged into PBS and endotoxin removed using high capacity
endotoxin removal columns (Thermo Fisher Scientiﬁc) then ﬁlter sterilized.
Western and far western blotting
Standard protocols for western blotting were used. Far westerns involved
incubating polyvinylidene ﬂuoride membranes for 1 h with hCLEC14A-
ECD-Fc (2 μg/ml), CD248-ECD-Fc (2 μg/ml), or MMRN2FL-transfected lysates
(6 × 106 HEK293T cells/ml of lysis buffer) (diluted 1:50). Epitope tags of each
protein probe were detected with secondary antibodies as standard.
Cell culture, transfections and transductions
HUVECs were isolated from umbilical cords collected at the Birmingham
Women’s Hospital with consent and cultured as described.2 HUVEC
experiments used at least three distinct preparations from different cords.
HEK293T were cultured as described.3 Transfections and lentiviral
transductions performed as previous.4
Cell surface biotinylation and immunoprecipitation
Transfected HEK293T washed twice with PBS (Mg2+ and Ca2+), then EZ-Link
Sulfo-NHS-Biotin (Thermo Fisher Scientiﬁc #21217) was incubated at 1 mg/
ml in PBS for 30 min, biotinylation reaction quenched using 100 mM
glycine and cells washed twice with PBS were immunoprecipitated with 2–
5 μg of antibody or Fc-tagged protein as described.3
Sequence alignment and structure prediction modelling
Protein sequences were aligned using a described algorithm.37 iTASSER
servers were used to predict the three-dimensional molecular structure of
CLEC14A-CTLD (Accession number Q86T13 residues 21–173). The model
with the highest C-score (0.05) and organized structure was chosen.
Immunoﬂuorescence staining and analysis
HUVEC on gelatin-coated coverslips were cultured for 6 days, media
replaced every 2 days, ﬁxed and blocked as described without
permeabilization.38 Incubated with anti-MMRN2 (Abnova, 4 μg/ml) and
hFc, mCD248-ECD-Fc or CLEC14A-ECD-Fc (all 20 μg/ml) for 2 h. Detection
antibodies; anti-human alexaﬂuor-555 and anti-mouse alexaﬂuor-488
incubated for 1.5 h. Human pancreatic tumour sections were cleared of
parafﬁn, rehydrated and antigen retrieved in Tris-EDTA pH 9.0 for 1 h
(96 °C), blocked in 2.5% horse serum PBS 30 min, anti-MMRN2 (Abcam,
0.45 μg/ml), anti-CLEC14A (R&D, 50 μg/ml), anti-CD248 B1.35 (1:5 dilution)
1 h. Detection antibodies: anti-rabbit alexaﬂuor-647, anti-mouse alexaﬂuor-
488, anti-sheep alexaﬂuor-546. Frozen tumour sections stained with anti-
CD31 (MEC13.3, 75 ng/ml) and anti-rat alexaﬂuor-488. Imaged using
confocal microscope Zeiss LSM-780 with Argon and He/Ne lasers, 40x or
63x/1.40 water immersion objectives. Images displayed as maximum
intensity projections. Vessel analysis was as described (Supplementary
Figure S9).
Flow cytometry
Detached HUVEC or transfected HEK293T (5 × 105) were stained with
antibody or recombinant protein (20 μg/ml). In blocking experiments,
hCLEC14A-ECD-Fc was incubated with 2 × molar excess of antibody or
recombinant protein for 1 h (4 °C). In GFP-tagged overexpressions, GFP+
cells were gated for analysis. Detection reagents; anti-hFc-FITC (1:100),
streptavidin-PE (1:100), anti-mouse alexaﬂuor-555 (1:100). The samples
were analysed on a FACSCalibur (BD Biosciences).
ELISA assay
The 96-well plates were coated with mCD248-ECD-Fc (400 ng) in PBS
overnight (4 °C), blocked (PBS 3% (w/v) BSA), then MMRN2FL transfected
HEK293T lysates (6 × 106 cells/ml) added diluted in PBS (1:50). CLEC14A-
ECD-Fc (200 ng) or anti-His antibodies (200 ng), then for CLEC14A-ECD-Fc,
C2 (400 ng) was incubated. Binding detected with anti-mouse-HRP
(1:5000), visualized using BM Blue POD substrate (Roche).
Adhesion assay
MMRN2495− 674, MMRN2495−603 or BSA (2 μg) coated on 96-well plates
overnight in PBS (37 °C). Then blocked (PBS 3% BSA) and dissociated
HUVEC (50 000/well) added for 4 h (37 °C), washed ﬁve times, ﬁxed (4%
paraformaldehyde) and stained (0.5% crystal violet solution; Sigma-
Aldrich). Images taken (Leica DM IL microscope and 2M Xli camera) and
absorbance measured at 590 nm.
Matrigel and co-culture assays
Performed as described,3,38,39 recombinant proteins added at 20 μg/ml
in PBS.
Mouse tumour implantation assays
A total 106 transduced LLC were subcutaneously injected into the right
ﬂank of male C57BL/6 mice aged 8− 10 weeks old. After 2 weeks or when
tumour size limit of 1200 mm3 was reached, the animals were killed,
tumours excised and weights determined. The mice were housed at the
Birmingham Biomedical Services Unit. Animal experimentation was carried
out in accordance with Home Ofﬁce License PPL70/8704 held by RB.
Statistical analysis
Statistical tests were calculated using Graphpad Prism software and were
all two-tailed tests, all replicates are biological replicates and n numbers
are stated in the ﬁgure legends.
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